Intrahepatic CholangiocarcinomaPhase 2PM-CARENCT06375915
Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy
A Phase 2 study testing radioembolization with Y-90, Durvalumab and Cisplatin in people with Intrahepatic Cholangiocarcinoma, run by Francesco De Cobelli at 4 sites in Italy.
Trial summary
Underlying disease mechanisms are fundamental for correct treatment selection and patient management in highly invasive and debilitating non-transmissible diseases. Even though overall disease burden of cancer may have decreased due to a higher degree of awareness, the availability of high-quality healthcare and early… Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Intrahepatic Cholangiocarcinoma
- What is being tested?
- radioembolization with Y-90, Durvalumab and Cisplatin
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 33 participants
- Where
- 4 sitesItaly
- Study dates
- 30 Apr 2024to May 2027
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization (European Union [EU] Data Privacy Directive) obtained from the patient/legal representative prior to performing any protocol related procedures, including screening evaluations.
- Patients with liver predominant intrahepatic cholangiocarcinoma with intermediate/high rate of early recurrence calculated according to https://k-sahara.shinyapps.io/Veryearlyrecurrence/.
- Patients aged > 18 to ≤ 80 at time of study entry;
- Body weight >30kg
- Suspicion or biopsy confirmed diagnosis of iCC, not previously treated with systemic or surgical therapies, including not previously enrolled in another clinical study with an investigational product;
- Preserved liver function as defined as: Child Pugh Class A; Model for End Stage Liver Disease Score (MELD) <10; Future Liver Remnant (FLR) uptake function ≥2.7%/min/m2 on technetium- 99m mebrofenin hepatobiliary scintigraphy and FLR volume> 30% of total functional liver volume for a normal liver, or > 40% of total functional liver volume if the liver has been damaged by chronic liver disease, cholestasis, steatohepatitis or diabetes;
Show all 14Show fewer
- No technical contraindications to TARE as confirmed by pre-procedural angiographic and scintigraphy;
- DNA tests for hepatitis B virus (HBV) and RNA tests for hepatitis C virus (HCV) negative at Screening;
- Adequate heart and lung function;
- Eastern Cooperative Oncology Group (ECOG) Performance Score 0 or 1;
- Adequate renal and hepatic function as indicated by: serum creatinine <2x upper limit of normal and estimated glomerular filtration rate (eGFR) ≥30ml/min or 1.73m2; measured creatinine clearance (CL) >40 mL/min or calculated creatinine CL>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976*) or by 24-hour urine collection for determination of creatinine clearance; Alkaline phosphatase (ALP), alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≤ 5 times the upper limit of normal (ULN) and total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (this will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician);
- Hemoglobin ≥9 g/dL, platelet count ≥75,000/mm3, absolute neutrophil count (ANC) ≥ 1.0 x 109 /L
- Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
- Must have a life expectancy of at least 12 weeks
Who cannot join
- Cancer classified as a combined or mixed type (HCC hepatocelular carcinoma and ICC) at screening -histopathological examination;
- Child-Pugh class B or more or evidence of severe portal hypertension at screening or at any time up to and including baseline;
- History of major gastrointestinal bleeding that required medical intervention within 30 days prior to screening or baseline;
- Known hypersensitivity to tumor specific chemotherapy agents used during the study;
- Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients;
- Previous allogeneic bone marrow transplant, kidney or liver transplant, i.e. - history of allogenic organ transplantation;
Show all 30Show fewer
- Active viral, bacterial or fungal infection, clinically relevant for the assessment of suitability;
- Current history or evidence of neuropsychiatric diseases, including depression, schizophrenia,bipolar disorder, impaired cognitive function, dementia, or suicidal tendency;
- Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis,etc]). The following are exceptions to this criterion: Patients with vitiligo or alopecia; Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement; Any chronic skin condition that does not require systemic therapy; Patients without active disease in the last 5 years may be included but only after consultation with the study physician; Patients with celiac disease controlled by diet alone;
- History of severe cardiovascular disease such as a previous stroke, coronary artery disease requiring surgery, or unresolved arrhythmias within the past 6 months;
- Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms calculated from 3 ECGs (within 15 minutes at 5 minutes apart);
- Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events (AEs) or compromise the ability of the patient to give written informed consent
- History of another primary malignancy except for: malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of IP and of low potential risk for recurrence; Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; Adequately treated carcinoma in situ without evidence of disease
- History of leptomeningeal carcinomatosis;
- Evidence of any hematological malignancy;
- History of active primary immunodeficiency - Positive for human immunodeficiency virus type 1 or 2 (HIV-1, HIV-2) (serum or RNA) - and / or hepatitis B virus surface antigen (HBsAg) positive and/or active Treponema pallidum infection or Mycoplasma (active tuberculosis infection); Known active hepatitis infection, positive hepatitis C virus (HCV) antibody, hepatitis B virus (HBV) surface antigen (HBsAg) or HBV core antibody (anti-HBc), at screening. Participants with a past or resolved HBV infection (defined as the presence of anti-HBc and absence of HBsAg) are eligible. Participants positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA;
- Alcohol abuse in the 2 months prior to study or other substance abuse in the 6 months prior to the study;
- Pregnant or breastfeeding women or women planning to become pregnant;
- Known bleeding diathesis or history of abnormal bleeding or any other known coagulation abnormality that may contraindicate future surgery or biopsies;
- Use of systemic immunosuppressants or steroids (prednisone equivalent> 10 mg/day);
- Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion: Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection); Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent; Steroids as premedication for hypersensitivity reactions;
- Active autoimmune conditions
- Patients weighing <30kg will be excluded from enrolment;
- Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients;
- Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of Investigational product (IP). Note: Local surgery of isolated lesions for palliative intent is acceptable.
- Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 90 days after the last dose of IP and up to 90 days after the last dose;
- Presence of Hepatopulmonary shunt >20% at diagnostic angiography/99mTC-MAA.
- Prior randomisation or treatment in a previous durvalumab clinical study regardless of treatment arm assignment;
- Presence of Hepatopulmonary shunt >20% at diagnostic angiography/99mTC-MAA;
- Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
Trial locations and contacts
4 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Italy4 sites, 4 recruiting
- Recruiting
ASST Papa Giovanni XXIII
Bergamo, 24127
Paolo Marra, MD, +39035267111, pmarra@asst-pg23.it
Paolo Marra, MD
- Recruiting
Department of Radiology, IRCCS Ospedale San Raffaele
Milan, 20132
Francesco De Cobelli, MD, +39022643 ext. 2529, decobelli.francesco@hsr.it
Stephanie Steidler, PhD, +39022643 ext. 6111, steidler.stephanie@hsr.it
- Recruiting
Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli
Naples, 80131
Francesco Giurazza, MD, +390817473828, francesco.giurazza@aocardarelli.it
Francesco Giurazza, MD
- Recruiting
Azienda Ospedaliero Universitaria Pisana
Pisa, 56126
Laura Crocetti, MD, +39050997318, Laura.crocetti@med.unipi.it
Laura Crocetti, MD
About this study
Official title: Single Arm, Multicenter Phase II Study Investigating the Efficacy and Safety of a Novel Therapeutic Scheme in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization in Combination With CisGem and Durvalumab (MEDI4736)
Underlying disease mechanisms are fundamental for correct treatment selection and patient management in highly invasive and debilitating non-transmissible diseases. Even though overall disease burden of cancer may have decreased due to a higher degree of awareness, the availability of high-quality healthcare and early diagnosis may become challenging in certain neoplasms. Cholangiocarcinoma is usually diagnosed at advanced stages due to non-specific presentation and is frequently refractory to chemotherapy, causing a massive impact on patients and their families. Surgery is currently the only curative treatment but is available to only approximately 30% of patients. The combination of interventional- and immune-oncology to standard of care creates the perfect substrate for synergistic mechanisms to fight tumor growth; in situ cell death following transarterial embolization(TARE) elicits immune mediated response, inflammatory response and biomarkers of oxidative stress and increases antigen presenting T-cells which an anti-anti progam death ligand (PD-L)1 can bind to; standard of care can then add on with its known effects.The rationale of a combined- locoregional and systemic - treatment lies in the synergistic effects of each of the treatments.
Read the detailed description
Tumors are highly selective and well defined abnormal cellular proliferations in which microenvironment plays an important role in response to treatment. Intrahepatic Cholangiocarcinoma (iCCA), a tumor derived from the epithelia cells of the bile duct, is particularly invasive and malignant. Personalized treatment options with documented efficacy in patients with iCCA are still not available due to the complex and heterogenous molecular pathogenesis which has not been holistically described. Disease models have limited reproducibility; underlying chronic cholestatic disease, chronic inflammation and risk factors contribute to the complexity and diversity of tumor microenvironment. Although novel systemic therapeutic agents show improvement compared to standard of care chemotherapy, a significant percentage of patients still does not respond to treatment, maybe due to molecular/immunologic features which confer resistance. Local treatment prior to systemic therapy has shown to induce subtle changes in the tumor microenvironment and a systemic immune response: engagement of the immune system may therefore lead to enhanced and long term immunosurveillance and therefore, lasting benefits for cancer patients.
Combined systemic treatment with an anti PD-L1, that binds to the programmed cell death protein 1, and the standard of care (SOC) protein kinase inhibitor sorafenib and gemcitabine (which inhibits DNA synthesis), have been used in clinical trials for other primary liver indications and in patients with biliary tract cancers (TOPAZ trial).
Radioembolization (TARE) combines the embolization properties of microspheres with the radiant effect of Yttrium-90 (Y-90). The locally treated tumor tissue is left in place and releases tumor-associated antigens and danger-associated molecular peptides originating from dead or dying cancer cells which promote the activation of antigen presenting cells and anti-tumor CD8+T cells. The resulting development of a systemic immune response following local treatment may lead to tumor regression at different sites than the one treated locally, leading to the so-called abscopal effect.
Comprehensive evaluations in patients undergoing combined treatment may allow a better understanding of tumor pathophysiology as well as the optimization of combined treatment schemes.
This study will investigate the efficacy, primary endpoint overall response rate according to mRECIST (modified Response Evaluation Criteria in Solid Tumors) , and safety of the association of locoregional radioembolization followed by the combination of standard of care (SOC) chemotherapy with Cisplatin and Gemcitabine and durvalumab in patients with liver predominant unresectable intrahepatic cholangiocarcinoma. The biological profile of patients prior to and following locoregional treatment and the effect of systemic therapy will be characterized in terms of potential biomarkers such as quantitative non-invasive radiological based parameters, tumor tissue profiling and evaluation of biological substrates to help define and stratify patients with higher response and better outcome.
- Conditions
- Intrahepatic Cholangiocarcinoma
- Being tested
- radioembolization with Y-90, Durvalumab, Cisplatin, Gemcitabine
- Keywords
- intrahepatic cholangiocarcinoma, precision medicine, combined treatment, radioembolization (TARE), intrahepatic cholangiocarcinoma (iCC), immunotherapy, immunogenicity
- Medical subject headings
- Cholangiocarcinoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
radioembolization with Y-90Radiation
Radioembolization with Y-90 will be performed in nominal day 0
DurvalumabDrug
Following radioembolization, for 6 cycles -intravenous infusion on day 1 of each cycle
CisplatinDrug
Following radioembolization, for 6 cycles -intravenous infusion on day 1 and 8 of each cycle
GemcitabineDrug
Following radioembolization, for 6 cycles -intravenous infusion on day 1 and 8 of each cycle
| Study group | Role | What they receive |
|---|---|---|
| tretament arm | Experimental | Single arm treatment Receives: Radiation: radioembolization with Y-90; Drug: Durvalumab; Drug: Cisplatin; Drug: Gemcitabine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall response rate (ORR)
mRECIST criteria on imaging (modified Response Evaluation Criteria in Solid Tumors criteria)
Measured: 6 months post TARE
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Measured: Through study completion, an average of 2 years
Secondary outcomes (17)
Median progression free survival
mRECIST criteria
Measured: Through study completion, an average of 12 months
Overall response rate
mRECIST criteria
Measured: 3 months post TARE
Overall response rate
RECIST 1.1 criteria
Measured: 3 months post TARE
Overall response rate
mRECIST
Measured: Approximately 6 months post TARE
Overall response rate
RECIST 1.1 criteria
Measured: Approximately 6 months post TARE
Tumor circulating markers tumor tissue-based markers tumor circulating markers tumor tissue-based markers
Cytokine profile assay
Measured: At the begining of Cycle 1, 2, 3, 4, 5, 6 (each cycle is 21 days)
Tumor circulating markers
Flow cytometry analysis
Measured: At the begining of Cycle 1, 2, 3, 4, 5, 6 (each cycle is 21 days)
Tumor tissue based evaluation
Biopsy - histopathology diagnosis
Measured: During study conduction, at baseline
Tumor tissue-based markers tumor tissue-based markers tumor circulating markers tumor tissue-based markers
Biopsy - gene expression
Measured: During study conduction, at baseline
Tumor tissue-based markers tumor tissue-based markers tumor circulating markers tumor tissue-based markers
Biopsy - gene expression
Measured: During study conduction, prior to the begining of Cycle 1 (each cycle is 21 days)
Tumor tissue-based markers tumor circulating markers tumor tissue-based markers
Biopsy - immune landscape
Measured: During study conduction, at baseline
Tumor tissue-based markers tumor circulating markers tumor tissue-based markers
Biopsy - immune landscape
Measured: During study conduction, prior to the begining of Cycle 1 (each cycle is 21 days)
Tumor tissue-based markers tumor circulating markers tumor tissue-based markers
Biopsy - Immuno histochemistry (IHC)
Measured: During study conduction, at baseline
Tumor tissue-based markers tumor circulating markers tumor tissue-based markers
Biopsy - Immuno histochemistry (IHC)
Measured: During study conduction, prior to the beginning of Cycle 1 (each cycle is 21 days)
Quantitative imaging based biomarkers
Software extracted quantitive parameters
Measured: Through study completion, an average of 2 years
Quantitative biomarkers
Imaging based software extracted radiomic features
Measured: Through study completion, an average of 2 years
Overall Survival (OS)
Overall Survival (OS)
Measured: Through study completion, an average of 2 years (right censored)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Apr 2024
- Study start30 Apr 2024
- Primary completionMay 2027 (estimated)
- Study completionMay 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Intrahepatic CholangiocarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 33 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Francesco De Cobelli
- Sponsor type
- University, hospital or other
- Collaborators
- Cardarelli Hospital, A.O. Ospedale Papa Giovanni XXIII, AOU Pisana, Pisa, Italy
- Responsible party
- Sponsor-investigator, Francesco De Cobelli, IRCCS San Raffaele
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06375915
- Sponsor's protocol ID
- PM-CARE
- Other IDs
- PNRR-MAD-2022-12375905
- Acronym
- PM-CARE
- Status last verified
- Sep 2026
- First submitted
- 4 Mar 2024
- Last updated
- 21 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Single Arm, Multicenter Phase II Study Investigating the Efficacy and Safety of a Novel Therapeutic Scheme in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization in Combination With CisGem and Durvalumab (MEDI4736)
- ClinicalTrials.gov ID
- NCT06375915
- Acronym / sponsor ID
- PM-CARE / PM-CARE
- Conditions
- Intrahepatic Cholangiocarcinoma
- Keywords
- intrahepatic cholangiocarcinoma, precision medicine, combined treatment, radioembolization (TARE), intrahepatic cholangiocarcinoma (iCC), immunotherapy, immunogenicity
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 33 participants (estimated)
- Lead sponsor
- Francesco De CobelliUniversity, hospital or other
- Collaborators
- Cardarelli Hospital, A.O. Ospedale Papa Giovanni XXIII, AOU Pisana, Pisa, Italy
- Study start
- 30 Apr 2024 (actual)
- Primary completion
- May 2027 (estimated)
- Study completion
- May 2027 (estimated)
- First posted
- 19 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Underlying disease mechanisms are fundamental for correct treatment selection and patient management in highly invasive and debilitating non-transmissible diseases. Even though overall disease burden of cancer may have decreased due to a higher degree of awareness, the availability of high-quality healthcare and early diagnosis may become challenging in certain neoplasms. Cholangiocarcinoma is usually diagnosed at advanced stages due to non-specific presentation and is frequently refractory to chemotherapy, causing a massive impact on patients and their families. Surgery is currently the only curative treatment but is available to only approximately 30% of patients. The combination of interventional- and immune-oncology to standard of care creates the perfect substrate for synergistic mechanisms to fight tumor growth; in situ cell death following transarterial embolization(TARE) elicits immune mediated response, inflammatory response and biomarkers of oxidative stress and increases antigen presenting T-cells which an anti-anti progam death ligand (PD-L)1 can bind to; standard of care can then add on with its known effects.The rationale of a combined- locoregional and systemic - treatment lies in the synergistic effects of each of the treatments.
Detailed description
Tumors are highly selective and well defined abnormal cellular proliferations in which microenvironment plays an important role in response to treatment. Intrahepatic Cholangiocarcinoma (iCCA), a tumor derived from the epithelia cells of the bile duct, is particularly invasive and malignant. Personalized treatment options with documented efficacy in patients with iCCA are still not available due to the complex and heterogenous molecular pathogenesis which has not been holistically described. Disease models have limited reproducibility; underlying chronic cholestatic disease, chronic inflammation and risk factors contribute to the complexity and diversity of tumor microenvironment. Although novel systemic therapeutic agents show improvement compared to standard of care chemotherapy, a significant percentage of patients still does not respond to treatment, maybe due to molecular/immunologic features which confer resistance. Local treatment prior to systemic therapy has shown to induce subtle changes in the tumor microenvironment and a systemic immune response: engagement of the immune system may therefore lead to enhanced and long term immunosurveillance and therefore, lasting benefits for cancer patients.
Combined systemic treatment with an anti PD-L1, that binds to the programmed cell death protein 1, and the standard of care (SOC) protein kinase inhibitor sorafenib and gemcitabine (which inhibits DNA synthesis), have been used in clinical trials for other primary liver indications and in patients with biliary tract cancers (TOPAZ trial).
Radioembolization (TARE) combines the embolization properties of microspheres with the radiant effect of Yttrium-90 (Y-90). The locally treated tumor tissue is left in place and releases tumor-associated antigens and danger-associated molecular peptides originating from dead or dying cancer cells which promote the activation of antigen presenting cells and anti-tumor CD8+T cells. The resulting development of a systemic immune response following local treatment may lead to tumor regression at different sites than the one treated locally, leading to the so-called abscopal effect.
Comprehensive evaluations in patients undergoing combined treatment may allow a better understanding of tumor pathophysiology as well as the optimization of combined treatment schemes.
This study will investigate the efficacy, primary endpoint overall response rate according to mRECIST (modified Response Evaluation Criteria in Solid Tumors) , and safety of the association of locoregional radioembolization followed by the combination of standard of care (SOC) chemotherapy with Cisplatin and Gemcitabine and durvalumab in patients with liver predominant unresectable intrahepatic cholangiocarcinoma. The biological profile of patients prior to and following locoregional treatment and the effect of systemic therapy will be characterized in terms of potential biomarkers such as quantitative non-invasive radiological based parameters, tumor tissue profiling and evaluation of biological substrates to help define and stratify patients with higher response and better outcome.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| tretament arm | Experimental | Radiation: radioembolization with Y-90, Drug: Durvalumab, Drug: Cisplatin, Drug: GemcitabineSingle arm treatment |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (14 listed)
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization (European Union [EU] Data Privacy Directive) obtained from the patient/legal representative prior to performing any protocol related procedures, including screening evaluations.
- Patients with liver predominant intrahepatic cholangiocarcinoma with intermediate/high rate of early recurrence calculated according to https://k-sahara.shinyapps.io/Veryearlyrecurrence/.
- Patients aged > 18 to ≤ 80 at time of study entry;
- Body weight >30kg
- Suspicion or biopsy confirmed diagnosis of iCC, not previously treated with systemic or surgical therapies, including not previously enrolled in another clinical study with an investigational product;
Key exclusion criteria (30 listed)
- Cancer classified as a combined or mixed type (HCC hepatocelular carcinoma and ICC) at screening -histopathological examination;
- Child-Pugh class B or more or evidence of severe portal hypertension at screening or at any time up to and including baseline;
- History of major gastrointestinal bleeding that required medical intervention within 30 days prior to screening or baseline;
- Known hypersensitivity to tumor specific chemotherapy agents used during the study;
- Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| radioembolization with Y-90Radioembolization with Y-90 will be performed in nominal day 0 | Radiation | tretament arm |
| DurvalumabFollowing radioembolization, for 6 cycles -intravenous infusion on day 1 of each cycle | Drug | tretament arm |
| CisplatinFollowing radioembolization, for 6 cycles -intravenous infusion on day 1 and 8 of each cycle | Drug | tretament arm |
| GemcitabineFollowing radioembolization, for 6 cycles -intravenous infusion on day 1 and 8 of each cycle | Drug | tretament arm |
Primary outcome
Overall response rate (ORR)
Time frame: 6 months post TARE
mRECIST criteria on imaging (modified Response Evaluation Criteria in Solid Tumors criteria)
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time frame: Through study completion, an average of 2 years
17 secondary outcomes
Median progression free survival
Time frame: Through study completion, an average of 12 months
Overall response rate
Time frame: 3 months post TARE
Overall response rate
Time frame: 3 months post TARE
Overall response rate
Time frame: Approximately 6 months post TARE
Overall response rate
Time frame: Approximately 6 months post TARE
Tumor circulating markers tumor tissue-based markers tumor circulating markers tumor tissue-based markers
Time frame: At the begining of Cycle 1, 2, 3, 4, 5, 6 (each cycle is 21 days)
Tumor circulating markers
Time frame: At the begining of Cycle 1, 2, 3, 4, 5, 6 (each cycle is 21 days)
Tumor tissue based evaluation
Time frame: During study conduction, at baseline
Tumor tissue-based markers tumor tissue-based markers tumor circulating markers tumor tissue-based markers
Time frame: During study conduction, at baseline
Tumor tissue-based markers tumor tissue-based markers tumor circulating markers tumor tissue-based markers
Time frame: During study conduction, prior to the begining of Cycle 1 (each cycle is 21 days)
Tumor tissue-based markers tumor circulating markers tumor tissue-based markers
Time frame: During study conduction, at baseline
Tumor tissue-based markers tumor circulating markers tumor tissue-based markers
Time frame: During study conduction, prior to the begining of Cycle 1 (each cycle is 21 days)
Tumor tissue-based markers tumor circulating markers tumor tissue-based markers
Time frame: During study conduction, at baseline
Tumor tissue-based markers tumor circulating markers tumor tissue-based markers
Time frame: During study conduction, prior to the beginning of Cycle 1 (each cycle is 21 days)
Quantitative imaging based biomarkers
Time frame: Through study completion, an average of 2 years
Quantitative biomarkers
Time frame: Through study completion, an average of 2 years
Overall Survival (OS)
Time frame: Through study completion, an average of 2 years (right censored)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Intrahepatic Cholangiocarcinoma
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma
RecruitingPhase 3
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Biliary Tract Cancer
RecruitingPhase 2
Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial
Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant Therapy
RecruitingPhase 2
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
Liver Cancer, Intrahepatic Cholangiocarcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Department of Radiology, IRCCS Ospedale San Raffaele
Milan, Italy
Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli
Naples, Italy
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing radioembolization with Y-90, Durvalumab and Cisplatin in people with Intrahepatic Cholangiocarcinoma, run by Francesco De Cobelli at 4 sites in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 30 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall response rate (ORR) (time frame: 6 months post TARE). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2026.